Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Checkpoint Therapeutics

09/05/2025 15:18

Checkpoint Therapeutics Inc CKPT.OQ CKPT.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Checkpoint Therapeutics Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Checkpoint Therapeutics Inc is $4.10​, below​ its last closing price of $4.14. ​​​

This summary was machine generated May 9 at 14:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)